Product Name :
TCMDC-135051 TFA
Description:
TCMDC-135051 TFA is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 TFA prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector. TCMDC-135051 TFA has antiparasiticidal activity (EC50=320 nM).
CAS:
Molecular Weight:
585.61
Formula:
C31H34F3N3O5
Chemical Name:
4-[2-[5-(diethylaminomethyl)-2-methoxyphenyl]-1H-pyrrolo[2, 3-b]pyridin-4-yl]-2-propan-2-ylbenzoic acid;2, 2, 2-trifluoroacetic acid
Smiles :
COC1=CC=C(CN(CC)CC)C=C1C1=CC2=C(N1)N=CC=C2C1=CC(C(C)C)=C(C=C1)C(O)=O.OC(=O)C(F)(F)F
InChiKey:
QQIOPVVOIRCNFY-UHFFFAOYSA-N
InChi :
InChI=1S/C29H33N3O3.C2HF3O2/c1-6-32(7-2)17-19-8-11-27(35-5)25(14-19)26-16-24-21(12-13-30-28(24)31-26)20-9-10-22(29(33)34)23(15-20)18(3)4;3-2(4,5)1(6)7/h8-16,18H,6-7,17H2,1-5H3,(H,30,31)(H,33,34);(H,6,7)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
TCMDC-135051 TFA is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 TFA prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector.{{Lenacapavir} site|{Lenacapavir} Anti-infection|{Lenacapavir} Technical Information|{Lenacapavir} References|{Lenacapavir} supplier|{Lenacapavir} Cancer} TCMDC-135051 TFA has antiparasiticidal activity (EC50=320 nM).{{6PPD-Q} web|{6PPD-Q} Metabolic Enzyme/Protease|{6PPD-Q} Activator|{6PPD-Q} Technical Information|{6PPD-Q} Description|{6PPD-Q} supplier} |Product information|Molecular Weight: 585.PMID:23310954 61|Formula: C31H34F3N3O5|Chemical Name: 4-[2-[5-(diethylaminomethyl)-2-methoxyphenyl]-1H-pyrrolo[2, 3-b]pyridin-4-yl]-2-propan-2-ylbenzoic acid;2, 2, 2-trifluoroacetic acid|Smiles: COC1=CC=C(CN(CC)CC)C=C1C1=CC2=C(N1)N=CC=C2C1=CC(C(C)C)=C(C=C1)C(O)=O.OC(=O)C(F)(F)F|InChiKey: QQIOPVVOIRCNFY-UHFFFAOYSA-N|InChi: InChI=1S/C29H33N3O3.C2HF3O2/c1-6-32(7-2)17-19-8-11-27(35-5)25(14-19)26-16-24-21(12-13-30-28(24)31-26)20-9-10-22(29(33)34)23(15-20)18(3)4;3-2(4,5)1(6)7/h8-16,18H,6-7,17H2,1-5H3,(H,30,31)(H,33,34);(H,6,7)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|TCMDC-135051 TFA shows potent activity against P. berghei sporozoites in a liver invasion and development assay in which the compound shows a pEC50 value of 6.17 (EC50=0.40 μM) . The kinase assays using recombinant PvCLK3 (P. vivax) and PbCLK3 (P. berghei) show that TCMDC-135051 TFA has near-equipotent inhibition at these two orthologs, with pIC50 values of 7.47 (IC50=0.033 μM) and 7.86 (IC50=0.013 μM), respectively.|Products are for research use only. Not for human use.|